1. LncRNAs as novel indicators of patients' prognosis in stage i epithelial ovarian cancer: A retrospective and multicentric study
- Author
-
Luca Beltrame, Enrico Sartori, Franco Odicino, Chiara Romualdi, Eliana Bignotti, Stefano Cagnin, Dionyssios Katsaros, Lorenzo Ceppi, Maurizia Mello-Grand, Giulia Caratti, Paolo Martini, Enrica Calura, Ilaria Craparotta, Antonella Ravaggi, Maurizio D'Incalci, Sergio Marchini, Laura Mannarino, Lara Paracchini, Patrizia Perego, Robert Fruscio, Costantino Mangioni, Giovanna Chiorino, C Ghimenti, Gabriele Sales, Martini, P, Paracchini, L, Caratti, G, Mello-Grand, M, Fruscio, R, Beltrame, L, Calura, E, Sales, G, Ravaggi, A, Bignotti, E, Odicino, F, Sartori, E, Perego, P, Katsaros, D, Craparotta, I, Chiorino, G, Cagnin, S, Mannarino, L, Ceppi, L, Mangioni, C, Ghimenti, C, D'Incalci, M, Marchini, S, and Romualdi, C
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,Multivariate analysis ,Kaplan-Meier Estimate ,Carcinoma, Ovarian Epithelial ,Bioinformatics ,0302 clinical medicine ,lncRNA ,Neoplasms ,Neoplasms, Glandular and Epithelial ,Ovarian Neoplasms ,Tumor ,Glandular and Epithelial ,Middle Aged ,Prognosis ,Gene Expression Regulation, Neoplastic ,Adult ,Aged ,Biomarkers, Tumor ,Disease-Free Survival ,Female ,Humans ,Neoplasm Staging ,RNA, Long Noncoding ,Retrospective Studies ,ovarian cancer ,030220 oncology & carcinogenesis ,Biomarker (medicine) ,Long Noncoding ,medicine.medical_specialty ,03 medical and health sciences ,Median follow-up ,Internal medicine ,medicine ,Carcinoma ,Neoplastic ,business.industry ,Cancer ,Retrospective cohort study ,medicine.disease ,Confidence interval ,030104 developmental biology ,Gene Expression Regulation ,RNA ,business ,Ovarian cancer ,Biomarkers - Abstract
Purpose: Stage I epithelial ovarian cancer (EOC) represents about 10% of all EOCs and is characterized by good prognosis with fewer than 20% of patients relapsing. As it occurs less frequently than advanced-stage EOC, its molecular features have not been thoroughly investigated. We have demonstrated that in stage I EOC miR-200c-3p can predict patients' outcome. In the present study, we analyzed the expression of long non-coding RNAs (lncRNA) to enable potential definition of a non-coding transcriptional signature with prognostic relevance for stage I EOC. Experimental Design: 202 snap-frozen stage I EOC tumor biopsies, 47 of which relapsed, were gathered together from three independent tumor tissue collections and subdivided into a training set (n = 73) and a validation set (n = 129). Median follow up was 9 years. LncRNAs' expression profiles were correlated in univariate and multivariate analysis with overall survival (OS) and progression-free survival (PFS). Results: The expression of lnc-SERTAD2-3, lnc-SOX4-1, lnc-HRCT1-1, and PVT1 was associated in univariate and multivariate analyses with relapse and poor outcome in both training and validation sets (P < 0.001). Using the expression profiles of PVT1, lnc-SERTAD2-3, and miR-200c-3p simultaneously, it was possible to stratify patients into high and low risk. The OS for high- and low-risk individuals are 36 and 123 months, respectively (OR, 15.55; 95% confidence interval, 3.81–63.36). Conclusions: We have identified a non-coding transcriptional signature predictor of survival and biomarker of relapse for stage I EOC. Clin Cancer Res; 23(9); 2356–66. ©2016 AACR.
- Published
- 2017